RANCHO CORDOVA, Calif., Feb. 1, 2012 /PRNewswire/ -- ThermoGenesis Corp. (NASDAQ: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, today provided updates on two clinical evaluations involving its Res-Q® 60 BMC (Res-Q) system, a point-of-care platform designed for the preparation of cell concentrates from bone marrow.
Speaking at the Seventh International Conference on Cell Therapy for Cardiovascular Disease, Vijay Kumar, Ph.D., the Company's principal scientist and Manager of Research, said the initial data are encouraging for patients being treated in clinical evaluations for Critical Limb Ischemia (CLI) and long bone fractures with concentrates prepared by the Res-Q.
The studies covered in Kumar's presentation included:
"These outcomes demonstrate encouraging preliminary results with stem cell concentrates collected with our Res-Q System. CLI is a severe form of peripheral artery disease, with as many as 200,000 patients in the U.S. undergoing a limb amputation annually. Currently, there are more than 30 studies underway exploring stem cell therapy as an alternative treatment regimen for CLI patients. In addition, we are hopeful that stem cells will provide a new avenue for promoting the healing of serious bone fractures," said Matthew Plavan, Chief Executive Officer.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:
This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA and foreign regulatory approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2012, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2012. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
|SOURCE ThermoGenesis Corp.|
Copyright©2010 PR Newswire.
All rights reserved